Ravi Viswanathan
CIK 1479386 · last filed 2022-02-16
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$23.35B
Companies
28
Total Filings
71
Lifetime Open-Market Net
$112.58M
Filer Profile
Reported Address
1954 GREENSPRING DRIVESUITE 600
TIMONIUM, MD 21093
Related Filers
NewView Capital Fund I, L.P. — 6 joint filings, latest 2022-07-12
NewView Capital Partners I, LLC — 6 joint filings, latest 2022-07-12
FOREST BASKETT — 5 joint filings, latest 2018-10-24
PATRICK J KERINS — 5 joint filings, latest 2018-10-24
DAVID M MOTT — 5 joint filings, latest 2018-10-24
NEA 13 GP, Ltd — 5 joint filings, latest 2018-10-24
NEA Partners 13, Limited Partnership — 5 joint filings, latest 2018-10-24
NEW ENTERPRISE ASSOCIATES 13 LP — 5 joint filings, latest 2018-10-24
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses.
View filings on SEC EDGAR.
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| DUOL | 10%+ Owner | 5,239,835 | $153.33 | $803.42M | $0 | 1 | 2022-02-16 |
| ESTC | 10%+ Owner | 1,528,117 | $85.26 | $130.29M | $0 | 1 | 2018-10-10 |
| ASND | 10%+ Owner | 82,978,668 | $264.38 | $21.94B | $49.02M | 4 | 2018-09-10 |
| AVEO PHARMACEUTICALS, INC. (AVEO) Delisted | 10%+ Owner | 1,869,804 | $15.00 | $28.05M | $8.17M | 8 | 2018-08-22 |
| ARDX | 10%+ Owner | 3,082,186 | $3.56 | $10.97M | $23.33M | 3 | 2018-05-30 |
| Surface Oncology, Inc. (SURF) Delisted | 10%+ Owner | 3,312,877 | $1.07 | $3.54M | $2.00M | 1 | 2018-04-23 |
| TESARO, Inc. (TSRO) Delisted | 10%+ Owner | 9,681,129 | — | — | $73.31M | 6 | 2018-03-06 |
| Oruka Therapeutics, Inc. (ABIO) Delisted | 10%+ Owner | 0 | $28.80 | $0 | -$731.3K | 1 | 2018-02-27 |
| Cascadian Therapeutics, Inc. (CASC) Delisted | 10%+ Owner | 10,882,574 | — | — | $0 | 1 | 2018-02-22 |
| APPN | 10%+ Owner | 1,523 | $37.80 | $57.6K | -$66.07M | 4 | 2018-02-15 |
| SYNLOGIC, INC. (SYBX) Delisted | 10%+ Owner | 281,929 | $0.69 | $194.5K | $0 | 2 | 2018-01-26 |
| Care.com Inc (CRCM) Delisted | 10%+ Owner | 2,256,013 | — | — | $0 | 2 | 2017-11-08 |
| RYTM | 10%+ Owner | 4,359,956 | $102.00 | $444.72M | $9.35M | 1 | 2017-10-10 |
| Mersana Therapeutics, Inc. (MRSN) Delisted | 10%+ Owner | 325,606 | $29.08 | $9.47M | $15.00M | 1 | 2017-07-06 |
| MULESOFT, INC (MULE) Delisted | 10%+ Owner | 0 | — | — | $0 | 1 | 2017-03-22 |
| Achaogen, Inc. (AKAO) Delisted | 10%+ Owner | 5,215,128 | — | — | $6.75M | 1 | 2016-12-19 |
| Ra Pharmaceuticals, Inc. (RARX) Delisted | 10%+ Owner | 3,490,073 | — | — | $4.39M | 1 | 2016-10-31 |
| Roka BioScience, Inc. (ROKA) Delisted | 10%+ Owner | 321,681 | — | — | $4.60M | 3 | 2016-09-30 |
| Epizyme, Inc. (EPZM) Delisted | 10%+ Owner | 406,500 | $1.47 | $597.6K | $23.98M | 4 | 2016-01-12 |
| Avalo Therapeutics, Inc. (CERC.U) Delisted | 10%+ Owner | 594,245 | — | — | $0 | 1 | 2015-10-20 |
| SYNLOGIC, INC. (MIRN) Delisted | 10%+ Owner | 1,241,650 | — | — | $6.00M | 1 | 2015-10-06 |
| BOX | 10%+ Owner | 0 | $35.13 | $0 | $0 | 1 | 2015-01-29 |
| CVENT INC (CVT) Delisted | 10%+ Owner | 336 | $8.52 | $2.9K | -$46.25M | 5 | 2014-11-28 |
| DERM | 10%+ Owner | 3,433,810 | $7.42 | $25.50M | $1.11M | 1 | 2014-10-08 |
| Loxo Oncology, Inc. (LOXO) Delisted | 10%+ Owner | 1,789,420 | — | — | $3.00M | 1 | 2014-08-06 |
| Clovis Oncology, Inc. (CLVS) Delisted | 10%+ Owner | 11,399 | $0.08 | $926 | $17.11M | 2 | 2013-06-05 |
| WDAY | 10%+ Owner | 0 | $194.42 | $0 | $0 | 2 | 2013-04-11 |
| Millennial Media Inc. (MM) Delisted | 10%+ Owner | 8,196,614 | — | — | -$21.48M | 2 | 2012-10-30 |
Recent Filings · Page 2 of 8
71 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2018-05-09 | — | Mixed | — | $0 | |
| 2018-04-23 | Surface Oncology, Inc. (SURF) Delisted | Mixed | +3,312,877 | $2.00M | EDGAR |
| 2018-04-10 | AVEO PHARMACEUTICALS, INC. (AVEO) Delisted | Buy (P) | +920,976 | $2.12M | EDGAR |
| 2018-03-28 | ASND | Buy (P) | +6,571,164 | $12.59M | EDGAR |
| 2018-03-23 | ASND | Buy (P) | +1,268,508 | $2.42M | EDGAR |
| 2018-03-13 | — | U | −10,882,574 | $0 | |
| 2018-03-06 | TESARO, Inc. (TSRO) Delisted | Buy (P) | +145,532 | $8.35M | EDGAR |
| 2018-02-27 | Oruka Therapeutics, Inc. (ABIO) Delisted | Sell (S) | −1,460,209 | -$731.3K | EDGAR |
| 2018-02-22 | Cascadian Therapeutics, Inc. (CASC) Delisted | Conv (C) | +1,818,000 | $6.00M | EDGAR |
| 2018-02-15 | APPN | Mixed | +1,523 | $0 | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.